(Q37919717)

25 August 2017

1 reference

title

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma (English)

1 reference

25 August 2017

1 reference

1 reference

Niels W C J van de Donk

series ordinal

1

object named as

N W C J van de Donk

1 reference

25 August 2017

3

T Mutis

1 reference

25 August 2017

4

H M Lokhorst

1 reference

25 August 2017

S Kamps

2

1 reference

25 August 2017

19 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

26

1 reference

25 August 2017

2

1 reference

25 August 2017

199-213

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2011.214

25 August 2017

0 references

cites work

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Growth factors and antiapoptotic signaling pathways in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Antibody-maytansinoid conjugates for the treatment of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Human CD38: a (r)evolutionary story of enzymes and receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

MIF signal transduction initiated by binding to CD74

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

CD74 is a member of the regulated intramembrane proteolysis-processed protein family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

CD74 is expressed by multiple myeloma and is a promising target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Functions of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

CD200 is a new prognostic factor in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Role of decorin in the antimyeloma effects of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Bortezomib inhibits human osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

Immune complex-mediated antigen presentation induces tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

CD74 induces TAp63 expression leading to B-cell survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

CD200 expression in plasma cell myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.214

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.214

1 reference

PubMed ID

21852787

Dimensions Publication ID

25 August 2017

0 references

1 reference

PubMed ID

21852787